The company is developing DNA-based cancer therapies. Its stock was first traded on NASDAQ on May 29.
“Over the past year, our team has made significant headway to build a strong, cutting-edge, clinical-stage biotech company. As we become a NASDAQ-listed company, we are now able to communicate our progress with a broader audience, raise the visibility of OncoSec’s capabilities, and generate more value for our shareholders,” said Punit Dhillon, president and CEO.
“We are now in a better position to continue to advance our intratumoral immunotherapy technologies with the goal of one day benefiting cancer patients everywhere,” he added.
The traditional opening and closing ell ceremonies take place at the NASDAQ MarketSite in New York’s Times Square.
>> Subscribe to Times of San Diego’s free daily email newsletter! Click hereFollow Us: